NasdaqGS:ABSIBiotechs
Is Absci (ABSI) Overvalued Following Phase 1 Progress And A $100 Million Raise?
Absci (ABSI) has jumped into focus after reporting interim Phase 1 results for ABS-201 in androgenetic alopecia, alongside a roughly $100 million follow on equity raise supported by institutional and strategic investors.
See our latest analysis for Absci.
Absci’s recent ABS-201 update and $100 million equity raise come on top of a sharp re-rating, with a 30 day share price return of 93.37% and a 1 year total shareholder return of 276.75%. These moves point to strong momentum as investors...